logo
Dhan-Dhaanya Krishi Yojana committed to transforming lives of farmers: PM

Dhan-Dhaanya Krishi Yojana committed to transforming lives of farmers: PM

The 'Dhan-Dhaanya Krishi Yojana' will boost farm production in districts that are lagging behind and also increase the income of farmers, Prime Minister Narendra Modi said on Wednesday, stressing that his government is committed to transforming the lives of farmers.
The Union Cabinet earlier approved 'Prime Minister Dhan-Dhaanya Krishi Yojana' with an annual outlay of Rs 24,000 crore for six years to boost crop yields in 100 districts, benefiting about 1.7 crore farmers.
The scheme will kick start from October, during the rabi (winter) season.
In another Cabinet decision, the government enhanced the investment limit of state-owned NTPC to Rs 20,000 crore and also allowed public sector NLCIL to pump in Rs 7,000 crore in renewable energy projects.
Modi said it is a boost to India's efforts to strengthen renewable energy capacity.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Not covered in FTA, carbon tax may spoil in India-UK free trade mood; here's why
Not covered in FTA, carbon tax may spoil in India-UK free trade mood; here's why

First Post

time23 minutes ago

  • First Post

Not covered in FTA, carbon tax may spoil in India-UK free trade mood; here's why

Britain's proposed Carbon Border Adjustment Mechanism (CBAM) is not included in the FTA with India because London has not yet formally notified the tax. read more The free trade agreement between India and the UK does not cover Britain's proposed Carbon Border Adjustment Mechanism (CBAM). However, officials stated on Friday (July 25) that if such a tax is introduced later, India will have the right to take measures to offset its impact on domestic exports, reported Economic Times. The CBAM is not included in the agreement because Britain has not yet formally notified the tax. In December 2023, the UK announced plans to implement the CBAM starting in 2027. STORY CONTINUES BELOW THIS AD The issue was raised during negotiations for the Comprehensive Economic and Trade Agreement (CETA). 'If it is implemented and negates the trade benefits of India under the agreement, India will have the freedom to rebalance it. We can take counterbalancing measures. This much understanding has been made in the form of note verbale,' an official was quoted as saying by the ET.. A note verbale refers to a diplomatic communication exchanged between two countries. 'There is an understanding that in case the UK make it effective against India in future, then we will also have the right to take counterbalance measures… India can take away the concessions and there will be a mechanism for that,' the official further noted. India is also engaged in discussions with the European Union, which is planning its own CBAM. The two parties are negotiating a trade agreement, expected to be finalised this year. India has labelled the CBAM as a trade barrier. A carbon tax is considered a non-tariff barrier. The European Union has already implemented such a tax on imports exceeding a specific carbon emission threshold. For every tonne of excess carbon emission, a levy ranging from €1 to €100 per tonne is imposed. India and the United Kingdom (UK) signed the Free Trade Agreement (FTA) on Thursday (July 24) during PM Narendra Modi's visit to the UK. STORY CONTINUES BELOW THIS AD New Delhi and London concluded talks in May to reach a bilateral Free Trade Agreement, discussions for which first began in January 2022. As per the British government estimates, the FTA will boost its GDP by £4.8 billion ($6.5 billion) annually. Indian exports to the UK are expected to double by 2030.

India's Pharma Exports Have Shot Up By 92% In Last 6 Years: Minister
India's Pharma Exports Have Shot Up By 92% In Last 6 Years: Minister

India.com

time23 minutes ago

  • India.com

India's Pharma Exports Have Shot Up By 92% In Last 6 Years: Minister

New Delhi: Various schemes being implemented by the Centre to realise the vision of Aatmanirbhar Bharat in the pharmaceutical sector have resulted in India's exports of drugs and pharmaceuticals increasing by 92 per cent, from Rs 1,28,028 crore in FY2018-19 to Rs 2,45,962 crore in FY2024-25, the Parliament was informed on Friday. The schemes include the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme, the Production Linked Incentive (PLI) Scheme for Pharmaceuticals, the PLI Scheme for Bulk Drugs, Scheme for Promotion of Bulk Drug Parks, and Strengthening of Pharmaceutical Industry scheme, Minister of State for Chemicals and Fertilisers Anupriya Patel told the Lok Sabha in a written reply to a question. The PRIP scheme has been launched with an outlay of Rs 5,000 crore to transform India's Pharma MedTech sector from cost- to innovation-based growth by strengthening research and promoting industry-academia linkage for research and development in priority areas in drug discovery and development and medical devices. Under this scheme, seven Centres of Excellence (CoEs) have been set up, she said. The PLI Scheme for Pharmaceuticals aims to enhance India's manufacturing capabilities by increasing investment and production in the sector and contributing to product diversification to high-value goods in the pharmaceutical sector. The minister said that the scheme has enabled enhanced investment and production in eligible products. As of March 2025, the committed investment of Rs 17,275 crore targeted over the six-year period of the scheme stands substantially exceeded with a cumulative investment of Rs 37,306 crore made by the scheme's third year, and cumulative sales of approved products of Rs 2,66,528 crore have been made, including exports of Rs 1,70,807 crore. The PLI Scheme for Bulk Drugs, which has a total budgetary outlay of Rs 6,940 crore, aims to avoid disruption in the supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs for which there are no alternatives by reducing supply disruption risk due to excessive dependence on a single source. As of March 2025, the committed investment of Rs 3,938.5 crore under projects approved under the scheme for investment over the six-year production period of the scheme stands substantially exceeded with a cumulative investment of Rs 4,570 crore made by the scheme's third year, she further stated. The minister also highlighted that the government launched the Pradhan Mantri Bhartiya Janaushadhi Pariyojana scheme to make quality generic medicines available at affordable prices to all. Under the scheme, dedicated outlets known as Jan Aushadhi Kendras (JAKs) are opened across the country to provide medicines at prices that are about 50 per cent to 80 per cent lower than those of leading branded medicines in the market. Till June 6, 2025, a total of 16,912 JAKs have been opened, and on average, about 10 to 12 lakh persons visit these Kendras daily and avail of quality medicines at affordable prices. As many as 2,110 medicines and 315 surgicals, medical consumables and devices are under the scheme product basket, covering all major therapeutic groups, such as cardiovascular, anti-cancer, anti-diabetic, anti-infectives, anti-allergic and gastro-intestinal medicines and nutraceuticals. As a result of the scheme, in the last 11 years, estimated savings of about Rs 38,000 crore have accrued to citizens in comparison to the prices of branded medicines. Further, the scheme has provided self-employment to over 16,000 persons, including over 6,800 women entrepreneurs, the minister added.

Hyundai India Gets Rs 517.34 Cr Tax With Penalty Demand From GST Authority, Here's Why
Hyundai India Gets Rs 517.34 Cr Tax With Penalty Demand From GST Authority, Here's Why

News18

time30 minutes ago

  • News18

Hyundai India Gets Rs 517.34 Cr Tax With Penalty Demand From GST Authority, Here's Why

Last Updated: The company said there is no impact on its financial, operational or other activities due to the order and is reviewing the order and will exercise the right to file an appeal. Hyundai Motor India Ltd on Tuesday said it has received a demand of Rs 517.34 crore from tax authorities, along with penalty, for alleged short payment of GST compensation cess on its certain SUV models. The company has received an order from Commissioner (Appeals), CGST Dept, Tamil Nadu, confirming GST compensation cess demand of Rs 258.67 crore, along with penalty of Rs 258.67 crore, on the allegation of short payment of GST compensation cess on certain SUV models for the period September 2017 – March 2020, Hyundai Motor India Ltd said in a regulatory filing. Reacting to the demand, a company spokesperson said, 'HMIL is of the view that the amendment and the clarifications given by the Central Board of Indirect Tax and Customs (CBIC) to resolve the issue faced by the industry on this matter are in favour of the company. We are in the process of reviewing the order and will exercise the right to seek a legal remedy through an appropriate forum." The company asserted that there is no impact on its financial, operational or other activities due to the order and is reviewing the order and will exercise the right to file an appeal. . view comments First Published: July 26, 2025, 08:17 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store